UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025231
Receipt number R000028882
Scientific Title Comprehensive Geriatric Assessment study to determine an appropriate therapy for elderly patients with diffuse large B-cell lymphoma
Date of disclosure of the study information 2016/12/12
Last modified on 2022/06/16 11:05:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comprehensive Geriatric Assessment study to determine an appropriate therapy for elderly patients with diffuse large B-cell lymphoma

Acronym

CGAL study

Scientific Title

Comprehensive Geriatric Assessment study to determine an appropriate therapy for elderly patients with diffuse large B-cell lymphoma

Scientific Title:Acronym

CGAL study

Region

Japan


Condition

Condition

Diffuse large B-cell lymphoma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Purpose of the study is to evaluate comprehensive geriatric assessment and to find the risk factors and establish a scoring system to predict severe complications in association with treatment for the elderly patients with diffuse large B-cell lymphoma

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Relationship between CGA results and treatment outcomes(G3,4,5 adverce events)

Key secondary outcomes

1)Average relative dose intensity (ARDI)
2)Treatment completion rate
3)Complete response (CR)
4)Event-free survival(EFS)
5)Overall survival (OS)
6)Cause of death


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Newly-diagnosed untreated patient with histologically-proven DLBCL
A patient who gives an informed consent to participate in this study

Key exclusion criteria

A patient who is judged inadequate for this study by his/her physician

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Yasushi
Middle name
Last name Takamatsu

Organization

Fukuoka University

Division name

Division of Medical Oncology, Hematology and Infectious Disease

Zip code

814-0180

Address

7-45-1, Nanakuma, Jonan-ku, Fukuoka

TEL

092-801-1011

Email

yasushi@fukuoka-u.ac.jp


Public contact

Name of contact person

1st name Kazuo
Middle name
Last name Tamura

Organization

Fukuoka University

Division name

Division of Medical Oncology, Hematology and Infectious Disease

Zip code

814-0180

Address

7-45-1, Nanakuma, Jonan-ku, Fukuoka

TEL

092-801-1011

Homepage URL


Email

ktamura@fukuoka-u.ac.jp


Sponsor or person

Institute

Fukuoka University
Division of Medical Oncology, Hematology and Infectious Disease

Institute

Department

Personal name



Funding Source

Organization

Fukuoka University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Fukuoka University Hospital Clinical Research Assist Center

Address

7-45-1, Nanakuma, Jonan-ku, Fukuoka

Tel

092-801-1011

Email

kenji0715@adm.fukuoka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

福岡大学病院(福岡県)、九州がんセンター(福岡県)、産業医科大学病院(福岡県)、神奈川県立がんセンター(神奈川県)


Other administrative information

Date of disclosure of the study information

2016 Year 12 Month 12 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 07 Month 10 Day

Date of IRB

2013 Year 09 Month 09 Day

Anticipated trial start date

2013 Year 09 Month 01 Day

Last follow-up date

2017 Year 02 Month 28 Day

Date of closure to data entry

2017 Year 03 Month 31 Day

Date trial data considered complete

2017 Year 04 Month 30 Day

Date analysis concluded

2017 Year 05 Month 31 Day


Other

Other related information

84 patients have been registered and the results of MNA,CCI, ADL, IADL, HDS-R,and VES-13 have been collected and will be put into the computer to analyze.


Management information

Registered date

2016 Year 12 Month 12 Day

Last modified on

2022 Year 06 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028882


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name